GlucoTrack Inc (GCTK)

In the past six months, GlucoTrack, Inc. reported financial results for the six months ended June 30, 2025, noting a decrease in research and development expenses. The company expanded its clinical advisory team, elected a medical device executive to its Board, and announced participation in FORGETDIABETES. GCTK's stock price has been volatile, with a 52-week high of $468.00 and a low of $4.22. As of November 13, 2025, the stock price was $5.67, with a market capitalization of $5.16 million, and on November 20, 2025, the stock closed at $4.83.

The provided search results do not contain specific information regarding demand seasonality for GlucoTrack, Inc.'s products and services. The nature of diabetes management suggests a relatively consistent demand for glucose monitoring solutions, though product launches, regulatory approvals, and advancements in technology could influence demand at various times.

GlucoTrack, Inc. is a medical technology company focused on diabetes management through innovative glucose monitoring solutions, operating in the Healthcare sector and Medical/Dental Instruments industry. Their flagship product is the GlucoTrack® model DF-F, a non-invasive glucose monitoring device that uses ultrasound, electromagnetic, and thermal technologies to measure glucose levels via a small earlobe sensor. The company is also developing a long-term implantable continuous blood glucose monitoring (CBGM) system designed for insulin-dependent individuals.

GlucoTrack, Inc. was initially established in Israel in 2000 and later relocated its headquarters to Rutherford, New Jersey, United States. The GlucoTrack® Model DF-F received its European CE Mark in 2013, allowing sales in European markets. The company's current development efforts for its implantable CBGM system are primarily focused on the U.S. market.

There are no specific events detailed in the past year that have negatively impacted GlucoTrack, Inc.'s brand reputation. The company continues to focus on developing innovative solutions for diabetes management and advancing its non-invasive and implantable glucose monitoring technologies. Its participation in research initiatives like FORGETDIABETES could be seen as a positive.

Information regarding major institutional and individual owners was not explicitly detailed. Insider ownership was reported at 0.04%. Insider transactions in 2024 included buys by Paul Goode and Drew Sycoff.